The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancerClaudia von Arx, Lucia Del Mastro, Grazia Arpino et al.|Cancer Treatment Reviews|2022Cited by 115
Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial resultsSabino De Placido, Grazia Arpino, Mario Giuliano et al.|The Breast|2018Cited by 35
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approachesSara Parola, C. De Angelis, Vincenzo Di Lauro et al.|Annals of Oncology|2022Cited by 1